Head to Head Survey: Arcutis Biotherapeutics (NASDAQ:ARQT) & Jaguar Animal Health (NASDAQ:JAGX)

Jaguar Animal Health (NASDAQ:JAGX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation.

Risk & Volatility

Jaguar Animal Health has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Profitability

This table compares Jaguar Animal Health and Arcutis Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jaguar Animal Health	-187.88%	N/A	-131.45%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Valuation & Earnings

This table compares Jaguar Animal Health and Arcutis Biotherapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jaguar Animal Health	$11.51 million	0.14	-$53.43 million	($3,731.33)	-0.00
Arcutis Biotherapeutics	$463.98 million	7.27	-$16.14 million	$0.21	127.88

Arcutis Biotherapeutics has higher revenue and earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Jaguar Animal Health and Arcutis Biotherapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jaguar Animal Health	1	0	0	0	1.00
Arcutis Biotherapeutics	0	3	6	0	2.67

Arcutis Biotherapeutics has a consensus price target of $35.57, suggesting a potential upside of 32.46%. Given Arcutis Biotherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Jaguar Animal Health.

Insider & Institutional Ownership

12.0% of Jaguar Animal Health shares are owned by institutional investors. 0.2% of Jaguar Animal Health shares are owned by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Arcutis Biotherapeutics beats Jaguar Animal Health on 13 of the 14 factors compared between the two stocks.

About Jaguar Animal Health

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.